---
title: "Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295124828.md"
datetime: "2026-08-06T15:31:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295124828.md)
  - [en](https://longbridge.com/en/news/295124828.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295124828.md)
---

# Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma

Aug 6 (Reuters) - Regeneron Canada: \* REGENERON CANADA: LIBTAYO RECEIVES HEALTH CANADA APPROVAL FOR ADJUVANT TREATMENT OF HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA Source text: Further company coverage: (REGN.O)

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaboration](https://longbridge.com/en/news/295154296.md)
- [NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/295508474.md)
- [Corline partner Kardium wins Health Canada approval for Globe PFA system featuring CHS coating](https://longbridge.com/en/news/295366225.md)
- [12:37 ETREGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit](https://longbridge.com/en/news/294851069.md)
- [Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress](https://longbridge.com/en/news/295224384.md)